Sir,

Congenital muscular dystrophy, structural eye abnormalities, and cobblestone lissencephaly form the triad needed to make a diagnosis of Muscle-Eye-Brain disease (MEB, OMIM 253280), an autosomal recessive disorder. They present very early in life with hypotonia, weakness, structural eye abnormalities, and brain malformation. Cardiomyopathy develops late in the course of the disease and may contribute to morbidity late in life. We herein report a 19-year old patient with MEB and cardiomyopathy who presented with a stroke, possibly due to embolism.

A 19-year-old boy, previously diagnosed with congenital muscular dystrophy (CMD) presented with a recent young stroke with left hemiplegia due to a right parietal, middle cerebral artery territory infarct. He had developmental delay since birth. Defective vision was noticed at two years and six months of age. Bilateral high myopia, glaucoma and cataract were detected subsequently. He had a febrile seizure when aged five. Speech onset was at 3 years of age, with slow progression to phrases by 7 years. At 19 years, when questioned, he could barely answer in three-word sentences. Spontaneous speech was limited to voicing needs and uttering protests. He could comprehend simple one-step commands. Abstract thinking, mathematical ability, writing, reading, and reasoning were completely lacking. He could walk with support and was hyperactive. From early infancy, the mother noted weakness of all four limbs, with a proximal emphasis. Creatine phosphokinase values ranged from 300 to 5000 IU/L with a normal echocardiogram. His best-achieved motor milestone was walking with support.

Magnetic resonance images (MRI) of the cerebrum revealed cobblestone lissencephaly in both frontal lobes and left occipital lobe, disorganized cerebellar folia with small cystic areas, an abnormal flattened pons, and ventricular enlargement. [Figure 1] This constellation of clinical

---

**Congenital Muscular Dystrophy due to POMGNT1 Mutation Presenting as Cardioembolic Stroke**

---

1. Rule out malarial infection in all patients presenting with fever and CVT, especially in endemic regions.

2. Plasmodium vivax infections can also lead to vascular anomalies, and due efforts will be made to conceal their identity, but understand that their names and initials will not be published.

3. Early treatment with parenteral artesunate usually leads to good functional outcomes.

---

**References**

1. Investigation of cerebral malaria: Prognostic importance of radiologic findings and correlation with post mortem findings. Radiology 2002;224:811‑6.

2. World Health Organization. Severe falciparum malaria. World Health Organization, communicable diseases cluster. Trans R Soc Trop Med Hyg2000;94:S1‑90.

3. Clark IA, Alleva LM. Is human malarial coma caused, or merely deepened, by sequestration? Trends Parasitol2009;25:314‑8.

4. Cordoliani YS, Sarrazin JL, Felten D, Caumes E, Leveque C, Fisch A. Artesunate for severe Plasmodium falciparum‑infected erythrocytes

---

**Conflicts of interest**

Nil.

---

**Financial support and sponsorship**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have anonymity cannot be guaranteed.

---

**Declaration of patient consent**

9. Francischetti IM, Seydel KB, Monteiro RQ, Whitten RO, Erexson CR, et al. 2007;5:155‑65.

---

**Figures**

1. This constellation of clinical
Figure 1: (a) Axial T1 W images showing cobble stone lissencephaly in the left occipital lobe. (b) Axial T1W images showing cobble stone lissencephaly in bilateral frontal lobes. (c) Sagittal T2W images showing disorganized cerebellar folia with small cystic areas – cortical dysplasia. (d) Sagittal T2W images showing abnormal flattened pons

and radiological findings suggested congenital muscular dystrophy with eye and brain involvement.

He was one of a sibship of three, with a normal brother and born of a nonconsanguineous marriage. The eldest sister had remained bedridden from the age of 2 and died of an unknown cause at 8 years and 6 months. There was no other affected family member.

When he now presented with stroke, in the setting of the muscle disease, a cardio embolic cause was suspected. Echocardiography revealed dilated left ventricle with severe global hypokinesia and an estimated ejection fraction of 30%, suggestive of dilated cardiomyopathy.

A clinical exome sequencing unfolded a pathogenic homozygous 3’ splice site variation in intron seven of the POMGNT1 gene (chr1:g. 46194653delT) that affects the invariant AG acceptor splice site of exon 8 (c.653-2del; ENST00000371992.1). The variant has not been reported in the 1000 genomes and gnomAD databases and has a minor allele frequency of 0.001% in the Medgenome internal database. The in silico prediction of the variant was damaging by Mutation Taster2.

We are reporting a young adult with stroke, cardiomyopathy, and congenital muscular dystrophy. Possibly his cardiac involvement could have been diagnosed earlier and cardioprotective drugs could have been given, so that his left ventricular dysfunction would not have become so severe.

One of the first studies on stroke in muscle diseases included 52 patients with Duchenne muscular dystrophy, 61 with myotonic dystrophy, and 14 with Becker muscular dystrophy followed up for up to 17 years. The prevalence of stroke in that cohort was only 1.5%. It is noteworthy that the population studied did not include Muscle-Eye-Brain disease. Among 665 patients with Duchenne muscular dystrophy, stroke occurred in five (0.75%). All five had dilated cardiomyopathy, and one of them had atrial fibrillation. Cardiac involvement in muscle diseases may affect the cardiac conduction system or the myocardium. Cardiomyopathy has been reported to be rare in MEB. Among a series of 105 children with congenital muscular dystrophy, only seven had cardiac involvement. All patients in that cohort who had POMGNT1 mutation had a normal cardiac and respiratory function.

CMDs have abnormally glycosylated dystroglycan. This group includes Walker-Warburg syndrome caused by mutations in POMT1 and POMT2, MEB caused by mutations in fukutin, CMD type 1C caused by mutations in FKRP, and CMD type 1D secondary to mutations in LARGE.

Mutation in the POMGNT1 gene can cause three different forms of muscular dystrophy. Type A3 is a severe congenital form with brain and eye anomalies, type B3 a less severe congenital form with impaired intelligence, myopia, optic atrophy, diffuse white matter changes, cerebellar cysts, and pontine hypoplasia, and type C3 presents with proximal muscle weakness, muscular hypertrophy, delayed motor development, myopia, and raised CPK. Possibly our child had type B3 as evidenced by the survival to the end of the second decade, cerebellar cysts, and pontine hypoplasia.

POMGNT1 mutation has also been seen in patients with nonsyndromic retinitis pigmentosa. Clement has reported a limb-girdle muscular dystrophy variant with onset at 12 years, normal intellect, and high myopia.

The brain MR imaging in children with POMGNT1 mutation may show polymicrogyria, cobblestone lissencephaly, absence of septum pellucidum, frontal white matter hyperintensities, corpus callosum dysplasia, cerebellar hypoplasia, and cerebellar cysts.

Cobblestone lissencephaly is pathognomonic of diseases affecting alphadystroglycan, resulting in a disease affecting muscle, eye, and brain. The gray-white difference will not be seen, and there will invariably be dysmyelination. It is the neuronal over migration into the subarachnoid space disrupting the glia limitans, that gives the cobblestone appearance on the surface.

A new-born with a muscle disorder needs to be accurately diagnosed to aid in genetic counseling. Patients with Walker-Warburg syndrome may not survive long, and the chance for genetic labeling may be lost. A child with muscle weakness, with eye and/or brain involvement, in addition, has in all likelihood Walker-Warburg syndrome, MEB disease, or Fukuyama congenital muscular dystrophy. Further characterization is needed by next-generation sequencing to pinpoint the diagnosis. The interdisciplinary team managing the patient should essentially have a cardiologist, as cardiomyopathy by itself adds to morbidity and as illustrated by this case can lead to embolic stroke. If the involvement of cardiac muscle is recognized early, the natural history and rate of progression can probably be altered.
Dear Editor,

We would like to describe a case of EMS presenting with a unique and rare entity. A 65-year-old woman presented to us with complaints of fatigue with skin rashes, undocumented intermittent fever, arthralgias, edema and sensory/motor abnormalities and hepatic dysfunction to systemic manifestations like fatigue, cognitive impairment with plaque-like T2 frontal white matter hyperintensities on magnetic resonance imaging of the brain to better acquaint clinicians and radiologists with this disorder falling on the spectrum of eosinophil-mediated ailments. First identified in 1989, approximately 1500 cases have been reported so far worldwide and almost twice that number failed to meet the CDC diagnostic criteria. EMS is caused by mutations in the FKRP gene which results in defective glycosylation and loss of laminin-binding activity in α-DG. Neurology 2004;62:1009-11. Mutations in the FKRP gene cause congenital muscular dystrophy, in cancer cells: A possible role to suppress cell proliferation. Int J Exp Path 2008;89:332–41.

There are no conflicts of interest.

Mary Iype, Omana Surendran Mithran1, Anitha Ayyappan2, Mathew Iype3
Departments of Pediatric Neurology and 1Cardiology, Government Medical College Thiruvananthapuram, Kerala, 2Senior Consultant Radiologist, HIND LABS, Medical College Campus, Thiruvananthapuram, Kerala, 3Department of Neurogenetics, Institute for Communicative and Cognitive Neurosciences, Palakkad, Kerala, India

Address for correspondence: Dr. Mary Iype, Department of Pediatric Neurology, Government Medical College Thiruvananthapuram, Kerala, India. E-mail: maryiypedr@gmail.com

REFERENCES
1. Biller J, Ionasescu V, Zellweger H, Adams HP Jr, Schultz DT. Frequency of cerebral infarction in patients with inherited neuromuscular diseases. Stroke 1987;18:805–7.
2. Hanajima R, Kawai M. Incidence of cerebral infarction in Duchenne muscular dystrophy. Muscle Nerve 1996;19:928.
3. Pane M, Messina S, Vaso G, Foley AR, Morandi L, Pegararo E, et al. Respiratory and cardiac function in congenital muscular dystrophies with alpha dystroglycan deficiency. Neuromuscul Disord 2012;22:685-9.
4. Kim DS, Hayashi YK, Matsumoto H, Ogawa M, Noguchi S, Murakami N, et al. POMT1 mutation results in defective glycosylation and loss of α-DG. Neurology 2004;62:1009-11.
5. van Reeuwijk J, Janssen M, vanden Elzen C, Beltran-Valero de Bernabé D, Sabatelli P, Merlini L, et al. POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet 2005;42:907-12.
6. Yamamoto T, Kato Y, Shibata N, Sawada T, Osawa M, Kobayashi M. A role of fukutin, a gene responsible for Fukuyama type congenital muscular dystrophy, in cancer cells: A possible role to suppress cell proliferation. Int J Exp Path 2008;89:332–41.
7. Topaloglu H, Brockington M, Yuva Y, Talim B, Haliloglu G, Blake D, et al. FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts. Neurology 2003;60:988-92.
8. Longman C, Brockington M, Torelli S, Jimenez-Mallebrera C, Kennedy C, Khalil N, et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of α-dystroglycan. Hum Mol Genet 2003;12:2853-61.
9. Clement EM, Godfrey C, Tan J, Brockington M, Torelli S, Feng L, et al. Mild POMGnTI mutations underlie a novel limb-girdle muscular dystrophy variant. Arch Neurol 2008;65:137–41.
10. Fu X, Yang H, Jiao H, Wang S, Liu A, Li X, et al. Novel copy number variation of POMGnTI associated with muscle-eye-brain disease detected by next-generation sequencing. Sci Rep 2017;7:7056.

Patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient’s relative has given consent for clinical information other than patient’s photograph to be reported in the journal. The patient and relatives understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Disclaimers
The views expressed in the submitted article are our own and not an official position of the institution.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Submitted: 27-Oct-2021 Revised: 31-Oct-2021 Accepted: 12-Dec-2021 Published: 25-Apr-2022

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

DOI: 10.4103/aiian.aiian_944_21